Order:
  1.  23
    Motivations, understanding, and voluntariness in international randomized trials.Nancy E. Kass, Suzanne Maman & Joan Atkinson - 2005 - IRB: Ethics & Human Research 27 (6):1.
  2.  32
    Access to treatment in hiv prevention trials: Perspectives from a south african community.Nicola Barsdorf, Suzanne Maman, Nancy Kass & Catherine Slack - 2009 - Developing World Bioethics 10 (2):78-87.
    Access to treatment, in HIV vaccine trials (HVTs), remains ethically controversial. In most prevention trials, including in South Africa, participants who seroconvert are referred to publicly funded programmes for treatment. This strategy is problematic when there is inadequate and uneven access to public sector antiretroviral therapy (ART) and support resources. The responsibilities, if any, of researchers, sponsors and public health authorities involved in HVTs has been hotly debated among academics, scholars, representatives of international organizations and sponsors. However, there is little (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  3.  32
    Testing Public Health Ethics: Why the CDC's HIV Screening Recommendations May Violate the Least Infringement Principle.Matthew W. Pierce, Suzanne Maman, Allison K. Groves, Elizabeth J. King & Sarah C. Wyckoff - 2011 - Journal of Law, Medicine and Ethics 39 (2):263-271.
    The least infringement principle has been widely endorsed by public health scholars. According to this principle, public health policies may infringe upon “general moral considerations” in order to achieve a public health goal, but if two policies provide the same public health benefit, then policymakers should choose the one that infringes least upon “general moral considerations.” General moral considerations can encompass a wide variety of goals, including fair distribution of burdens and benefits, protection of privacy and confidentiality, and respect for (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark